SARS-CoV-2 mRNA vaccine
Identification
- Name
- SARS-CoV-2 mRNA vaccine
- Accession Number
- DB15855
- Description
SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-22. It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy of Military Sciences. Preclinical studies in mice and non-human primates has shown that intramuscular administration of ARCoV elicited a Th1-biased cellular response and robust antibodies against SARS-CoV-22. Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- ARCoV
- External IDs
- SARS-CoV-2 mRNA vaccine
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [PubMed:32854391]
- Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, Guo Y, Sun SH, Fan H, Zu SL, Chen Q, He Q, Cao TS, Huang XY, Qiu HY, Nie JH, Jiang Y, Yan HY, Ye Q, Zhong X, Xue XL, Zha ZY, Zhou D, Yang X, Wang YC, Ying B, Qin CF: A Thermostable mRNA Vaccine against COVID-19. Cell. 2020 Sep 3;182(5):1271-1283.e16. doi: 10.1016/j.cell.2020.07.024. Epub 2020 Jul 23. [PubMed:32795413]
- Phase 1 Announcement [Link]
- mRNA vaccine approved for clinical trials [Link]
- External Links
- Not Available
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 17, 2020 20:58 / Updated on September 18, 2020 08:47